| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
RCM-1 targets Forkhead box M1 (FOXM1), a transcription factor that plays a critical role in cell proliferation and cell cycle progression. By inhibiting FOXM1, it prevents its nuclear localization and promotes its degradation. This leads to the inhibition of cellular proliferation. It is used in research on asthma and other chronic airway diseases.
|
|---|---|
| ln Vitro |
RCM-1 inhibits FOXM1, a transcription factor essential for goblet cell development from airway progenitor cells, from nuclear localization and enhances its proteasomal degradation. RCM-1 inhibits the expression of the STAT6 target genes Spdef and Foxa3, which are important transcriptional regulators of goblet cell development, and decreases IL-13 and STAT6 signaling in cultured airway epithelial cells [1].
In vitro, RCM-1 inhibits cellular proliferation by increasing the duration of cell cycle and mitosis in human and mouse cancer cell lines. It inhibits FOXM1 with an EC50 of 0.72 μM in U2OS cells. It reduces the growth of B16-F10 melanoma tumors in mice. |
| ln Vivo |
RCM-1 causes goblet cellization in mice exposed to home dust mites and interleukin 13 (IL-13). It does this by decreasing the production of proinflammatory cytokines, increasing lung compliance, and reducing airway resistance. RCM-1 suppresses IL-13 and STAT6 signaling in mice and inhibits the expression of the STAT6 target genes Foxa3 and Spdef [1].
In vivo, RCM-1 suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice. It reduces the growth of B16-F10 melanoma tumors and slows the growth of human H2122 lung adenocarcinoma in mice. It is a research compound for studying asthma and cancer. |
| Enzyme Assay |
The in vitro FOXM1 inhibition assay for RCM-1 involves measuring its ability to inhibit FOXM1 activity. This is typically done using a cell-based reporter assay or by measuring the expression of FOXM1 target genes. The EC50 for inhibition is determined.
|
| Cell Assay |
In vitro cellular assays for RCM-1 are performed on cancer cell lines, such as U2OS, B16-F10, and H2122 cells. Cells are treated with RCM-1, and cell proliferation, cell cycle progression, and apoptosis are measured. Its effects on FOXM1 localization and degradation are studied by immunofluorescence and Western blot.
|
| Animal Protocol |
In vivo animal experiments for RCM-1 are conducted in mouse models of asthma and cancer. The compound is administered, and its effects on airway inflammation, tumor growth, and survival are assessed.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic properties of RCM-1 are not extensively documented in the available literature. As a small molecule, it is expected to have reasonable membrane permeability. Its formulation for in vivo studies would typically involve solvents like DMSO.
|
| Toxicity/Toxicokinetics |
RCM-1 is considered a nontoxic inhibitor of FOXM1. Its toxicity data are limited, but its nontoxic profile suggests a favorable safety margin. As with all research chemicals, standard laboratory safety practices should be followed.
|
| References | |
| Additional Infomation |
RCM-1 is a research compound used to study FOXM1 in cancer and asthma. It is not an FDA-approved drug and is exclusively for research purposes. It is a valuable tool for investigating the role of FOXM1 in cell proliferation and disease.
|
| Molecular Formula |
C20H12N2OS4
|
|---|---|
| Molecular Weight |
424.582078933716
|
| Exact Mass |
423.983
|
| CAS # |
339163-65-4
|
| PubChem CID |
4273985
|
| Appearance |
Off-white to gray solid powder
|
| LogP |
5.6
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
580
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(CC(C1=CC=CS1)=O)C1=C(C#N)C(C2=CC=CS2)=CC(C2=CC=CS2)=N1
|
| InChi Key |
DCCYTKKDAZEVLY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H12N2OS4/c21-11-14-13(17-4-1-7-24-17)10-15(18-5-2-8-25-18)22-20(14)27-12-16(23)19-6-3-9-26-19/h1-10H,12H2
|
| Chemical Name |
2-{[2-Oxo-2-(thiophen-2-yl)ethyl]sulfanyl}-4,6-di(thiophen-2-yl)pyridine-3- carbonitrile
|
| Synonyms |
RCM-1 RCM1 RCM 1.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~39.26 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3553 mL | 11.7763 mL | 23.5527 mL | |
| 5 mM | 0.4711 mL | 2.3553 mL | 4.7105 mL | |
| 10 mM | 0.2355 mL | 1.1776 mL | 2.3553 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA